NEW YORK (GenomeWeb) – Fluxion Biosciences announced today that it has signed a distribution agreement for its BioFlux and IonFlux cellular analysis platforms with Harvard Bioscience.

BioFlux enables automated, high-throughput studies of cell-cell interactions, while microfluidics-based IonFlux is designed for ion channel research and drug discovery. Under the terms of the deal, Harvard Bioscience will offer the platforms to its customers in North America. Additional terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.